CVS Caremark Shakes Up GLP-1 Coverage as Zepbound Returns to the Formulary | iPharmaCenter

CVS Caremark is repositioning its GLP-1 weight management strategy to focus on both affordability and broader access, instead of simply expanding coverage as a routine update.

The key operational moves are the reintroduction of Zepbound (tirzepatide) as a preferred option on its commercial formularies from October 1, 2026, and the removal of the new-to-market block on Foundayo (orforglipron), an oral GLP-1 therapy, effective June 1, 2026.

These decisions indicate that CVS Caremark now sees enough improvement in net pricing and contracting to justify a controlled expansion of options in this high-cost category.

Why CVS added Zepbound bac in the formulary?

CVS Caremark’s decision to add Zepbound back to its formulary reflects a belief that it has reached better economic terms within the GLP-1 class, aligning clinical demand with budget realities. Initially, high prices and intense demand for GLP-1 agents created significant financial pressure, which led many plans to apply restrictions such as exclusions, tight prior authorization criteria, or step therapy. By taking a more restrictive stance early and using that position in negotiations with manufacturers, CVS Caremark has created room to reintroduce Zepbound as a preferred therapy while still presenting the outcome as a win on cost control for plan sponsors.

Also read: Top 10 Pharma Companies by Revenue in 2025

Foundayo coverage update

The lifting of the new-to-market block on Foundayo represents a second pillar of this strategy and signals readiness to integrate oral GLP-1 options into mainstream benefit designs once data and pricing are better understood.

Foundayo, as an oral therapy, offers a non-injectable alternative that may improve adherence or appeal to patients who prefer tablets over injections. This combination of a preferred injectable GLP-1 and a newly accessible oral GLP-1 gives plan sponsors more flexibility to tailor benefit structures, for example by tiering based on route of administration, preferred status, or specific clinical indications, while still managing utilization carefully.

What are the challenges in covering GLP-1 drugs by commercial plans in the US?

CVS Caremark openly acknowledges that GLP-1 pricing remains a central challenge. These therapies provide significant clinical benefit for weight management and cardiometabolic risk, but they also carry high costs and face large potential demand. Many employers and health plans have had to constrain coverage to maintain sustainable benefit programs.

CVS Caremark positions itself as an intermediary working to reduce net costs through manufacturer negotiations, in a pattern similar to its approach in other high-cost categories such as diabetes, autoimmune diseases, and dermatologic conditions. The company highlights a history of delivering strong savings for clients that adopt its template formularies and signals that the updated GLP-1 strategy is intended to extend this performance into the weight management space.

The formulary itself remains a central tool in this strategy. CVS Caremark’s commercial formularies are presented as templates that plan sponsors can adopt, modify, or override based on their own populations and risk tolerance. An independent Pharmacy and Therapeutics committee evaluates clinical appropriateness, and CVS Caremark layers on cost and access considerations to determine which drugs are preferred, which require prior authorization, and how step therapy is structured. This structure means that coverage of Zepbound and Foundayo still depends on sponsor-level decisions, even though CVS Caremark has opened the door for broader inclusion.

Also read: Top 10 U.S. healthcare companies by 2026 revenue

Because changes in GLP-1 coverage affect a large and vocal patient population, CVS Caremark emphasizes implementation and communication. The company plans to provide advance notice and support to customers, consultants, prescribers, and members so that transitions to covered therapies are as smooth as possible. This includes proactive outreach, educational materials, and clinical support programs that guide members toward therapies that are both clinically appropriate and covered under their specific benefit design. For members, the net effect is the potential for more options within GLP-1 therapy, combined with continued cost management through benefit design and utilization controls.